Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1093 to 1096 of 1096 entries
Sorted by: Best Match Show Resources per page
Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study.

Rheumatology (Oxford, England)

Mahmoud K, Zayat AS, Yusof MYM, Dutton K, Teh LS, Yee CS, D'Cruz D, Ng N, Isenberg D, Ciurtin C, Conaghan PG, Emery P, Edwards CJ, Hensor EMA, Vital EM.
PMID: 33792659
Rheumatology (Oxford). 2021 Nov 03;60(11):5194-5204. doi: 10.1093/rheumatology/keab288.

OBJECTIVES: To determine whether SLE patients with inflammatory joint symptoms and US synovitis/tenosyovitis achieve better clinical responses to glucocorticoids compared with patients with normal scans. Secondary objectives included identification of clinical features predicting US synovitis/tenosynovitis.METHODS: In a longitudinal multicentre...

Cite
Mahmoud K, Zayat AS, Yusof MYM, et al. Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. Rheumatology (Oxford). 2021;60(11):5194-5204doi: 10.1093/rheumatology/keab288.
Mahmoud, K., Zayat, A. S., Yusof, M. Y. M., Dutton, K., Teh, L. S., Yee, C. S., D'Cruz, D., Ng, N., Isenberg, D., Ciurtin, C., Conaghan, P. G., Emery, P., Edwards, C. J., Hensor, E. M. A., & Vital, E. M. (2021). Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. Rheumatology (Oxford, England), 60(11), 5194-5204. https://doi.org/10.1093/rheumatology/keab288
Mahmoud, Khaled, et al. "Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study." Rheumatology (Oxford, England) vol. 60,11 (2021): 5194-5204. doi: https://doi.org/10.1093/rheumatology/keab288
Mahmoud K, Zayat AS, Yusof MYM, Dutton K, Teh LS, Yee CS, D'Cruz D, Ng N, Isenberg D, Ciurtin C, Conaghan PG, Emery P, Edwards CJ, Hensor EMA, Vital EM. Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. Rheumatology (Oxford). 2021 Nov 03;60(11):5194-5204. doi: 10.1093/rheumatology/keab288. PMID: 33792659; PMCID: PMC8566203.
Copy Download .nbib Format: NLM
Discovery of new vascular disrupting agents based on evolutionarily conserved drug action, pesticide resistance mutations, and humanized yeast.

Genetics

Garge RK, Cha HJ, Lee C, Gollihar JD, Kachroo AH, Wallingford JB, Marcotte EM.
PMID: 34849907
Genetics. 2021 Aug 26;219(1). doi: 10.1093/genetics/iyab101.

Thiabendazole (TBZ) is an FDA-approved benzimidazole widely used for its antifungal and antihelminthic properties. We showed previously that TBZ is also a potent vascular disrupting agent and inhibits angiogenesis at the tissue level by dissociating vascular endothelial cells in...

Cite
Garge RK, Cha HJ, Lee C, et al. Discovery of new vascular disrupting agents based on evolutionarily conserved drug action, pesticide resistance mutations, and humanized yeast. Genetics. 2021;219(1)doi: 10.1093/genetics/iyab101.
Garge, R. K., Cha, H. J., Lee, C., Gollihar, J. D., Kachroo, A. H., Wallingford, J. B., & Marcotte, E. M. (2021). Discovery of new vascular disrupting agents based on evolutionarily conserved drug action, pesticide resistance mutations, and humanized yeast. Genetics, 219(1), . https://doi.org/10.1093/genetics/iyab101
Garge, Riddhiman K, et al. "Discovery of new vascular disrupting agents based on evolutionarily conserved drug action, pesticide resistance mutations, and humanized yeast." Genetics vol. 219,1 (2021). doi: https://doi.org/10.1093/genetics/iyab101
Garge RK, Cha HJ, Lee C, Gollihar JD, Kachroo AH, Wallingford JB, Marcotte EM. Discovery of new vascular disrupting agents based on evolutionarily conserved drug action, pesticide resistance mutations, and humanized yeast. Genetics. 2021 Aug 26;219(1). doi: 10.1093/genetics/iyab101. PMID: 34849907; PMCID: PMC8633126.
Copy Download .nbib Format: NLM
Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review.

British journal of cancer

Laszlo HE, Seward E, Ayling RM, Lake J, Malhi A, Stephens C, Pritchard-Jones K, Chung D, Hackshaw A, Machesney M.
PMID: 34903843
Br J Cancer. 2021 Dec 13; doi: 10.1038/s41416-021-01653-x. Epub 2021 Dec 13.

BACKGROUND: We evaluated whether faecal immunochemical testing (FIT) can rule out colorectal cancer (CRC) among patients presenting with 'high-risk' symptoms requiring definitive investigation.METHODS: Three thousand five hundred and ninety-six symptomatic patients referred to the standard urgent CRC pathway were...

Cite
Laszlo HE, Seward E, Ayling RM, et al. Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review. Br J Cancer. 2021;doi: 10.1038/s41416-021-01653-x.
Laszlo, H. E., Seward, E., Ayling, R. M., Lake, J., Malhi, A., Stephens, C., Pritchard-Jones, K., Chung, D., Hackshaw, A., & Machesney, M. (2021). Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review. British journal of cancer, . https://doi.org/10.1038/s41416-021-01653-x
Laszlo, Helga E, et al. "Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review." British journal of cancer vol. (2021). doi: https://doi.org/10.1038/s41416-021-01653-x
Laszlo HE, Seward E, Ayling RM, Lake J, Malhi A, Stephens C, Pritchard-Jones K, Chung D, Hackshaw A, Machesney M. Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review. Br J Cancer. 2021 Dec 13; doi: 10.1038/s41416-021-01653-x. Epub 2021 Dec 13. PMID: 34903843.
Copy Download .nbib Format: NLM
Recognition of the antigen-presenting molecule MR1 by a Vδ3.

Proceedings of the National Academy of Sciences of the United States of America

Rice MT, von Borstel A, Chevour P, Awad W, Howson LJ, Littler DR, Gherardin NA, Le Nours J, Giles EM, Berry R, Godfrey DI, Davey MS, Rossjohn J, Gully BS.
PMID: 34845016
Proc Natl Acad Sci U S A. 2021 Dec 07;118(49). doi: 10.1073/pnas.2110288118.

Unlike conventional αβ T cells, γδ T cells typically recognize nonpeptide ligands independently of major histocompatibility complex (MHC) restriction. Accordingly, the γδ T cell receptor (TCR) can potentially recognize a wide array of ligands; however, few ligands have been...

Cite
Rice MT, von Borstel A, Chevour P, et al. Recognition of the antigen-presenting molecule MR1 by a Vδ3. Proc Natl Acad Sci U S A. 2021;118(49)doi: 10.1073/pnas.2110288118.
Rice, M. T., von Borstel, A., Chevour, P., Awad, W., Howson, L. J., Littler, D. R., Gherardin, N. A., Le Nours, J., Giles, E. M., Berry, R., Godfrey, D. I., Davey, M. S., Rossjohn, J., & Gully, B. S. (2021). Recognition of the antigen-presenting molecule MR1 by a Vδ3. Proceedings of the National Academy of Sciences of the United States of America, 118(49), . https://doi.org/10.1073/pnas.2110288118
Rice, Michael T, et al. "Recognition of the antigen-presenting molecule MR1 by a Vδ3." Proceedings of the National Academy of Sciences of the United States of America vol. 118,49 (2021). doi: https://doi.org/10.1073/pnas.2110288118
Rice MT, von Borstel A, Chevour P, Awad W, Howson LJ, Littler DR, Gherardin NA, Le Nours J, Giles EM, Berry R, Godfrey DI, Davey MS, Rossjohn J, Gully BS. Recognition of the antigen-presenting molecule MR1 by a Vδ3. Proc Natl Acad Sci U S A. 2021 Dec 07;118(49). doi: 10.1073/pnas.2110288118. PMID: 34845016; PMCID: PMC8694053.
Copy Download .nbib Format: NLM
Showing 1093 to 1096 of 1096 entries